The Unseen Force

By Aaron Blocker
Senior Advisor: Advocacy / Market Access

Empowering Market Access for Rare Disease Therapies Through Patient Advocacy

Developing a life-saving therapy for a rare disease is a triumph of scientific innovation and perseverance. However, translating this groundbreaking research into real-world patient access is a complex undertaking, particularly in the multifaceted global market.

While scientific rigor, robust clinical data, and regulatory compliance are undeniably essential, there’s another, often underestimated, factor that can significantly impact the success of your rare disease therapy: patient advocacy.

The Crucial Role of Patient Advocacy Groups (PAGs) in Rare Disease Therapy Development

Rare diseases, by their very nature, affect a small percentage of the population. This limited patient pool often results in challenges in raising awareness, securing funding, and influencing healthcare policies. Patient advocacy groups (PAGs) emerge as vital champions for these underserved populations, playing an increasingly pivotal role at every stage of a rare disease therapy’s journey – from early development to market access and beyond.

1. Amplifying the Patient Voice and Shaping the Narrative

PAGs provide a powerful collective voice for patients and their families, raising awareness about the disease, its impact, and the urgent need for effective treatments. They actively engage with policymakers, healthcare professionals, and the public, shaping the narrative around the disease and advocating for:

Research funding
Accelerated regulatory pathways
Equitable access to therapies

This proactive engagement can influence healthcare decision-making and prioritize rare diseases on the public health agenda.

Patient advocacy groups are the heart and soul of the rare disease community. They provide essential support, information, and a sense of belonging to patients and families facing the challenges of a rare diagnosis.

-Eurodis-Rare Diseases Europe [Reference 1]

2. Informing Research and Development through Patient Insights

PAGs possess a wealth of knowledge about the patient experience, encompassing the day-to-day struggles, unmet needs, and the broader impact of the disease on patients’ lives. This invaluable insight, often referred to as the “patient voice,” can profoundly shape research and development efforts. By incorporating patient perspectives into:

Clinical trial design
Outcome measures
Treatment goals

Developers can ensure that therapies are truly patient-centric and address the most pressing needs of the community.

Patient engagement in research is not just a nice-to-have, it’s a must-have. Patients bring a unique perspective and expertise that can significantly improve the quality and relevance of research.

-European Patients' Academy on Therapeutic Innovation (EUPATI) [Reference 2]

3. Navigating the Complex Regulatory Landscape with Strategic Guidance

Regulatory agencies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have established frameworks for rare disease therapies, including incentives such as:

Orphan Drug Designation
Accelerated assessment procedures

However, navigating these intricate landscapes can be daunting. PAGs can offer invaluable guidance, providing insights into regulatory requirements, facilitating patient input in regulatory submissions, and advocating for policies that support the development and approval of rare disease therapies.

The EMA recognizes the importance of patient involvement in the regulatory process and actively seeks their input through various channels, including patient consultations and expert panels.

-European Medicines Agency (EMA) [Reference 3]

4. Driving Market Access and Reimbursement through Collaborative Efforts

Securing market access and reimbursement for rare disease therapies is a complex endeavour, often involving negotiations with health technology assessment (HTA) bodies and payers. PAGs play a crucial role in these discussions, providing evidence of the therapy’s value, advocating for fair pricing

and reimbursement policies, and ensuring that patient perspectives are considered in decisionmaking processes. By collaborating with PAGs, pharmaceutical companies can build stronger cases for reimbursement and ultimately improve access to their therapies for patients in need.

Patient advocacy groups are increasingly recognized as key stakeholders in the healthcare ecosystem, with a significant impact on market access and reimbursement decisions.

-The Patient Voice Institute [Reference 4]

The Rise of Patient Advocacy in the Asia-Pacific Region: A Force for Change in Rare Disease Care

The landscape of rare disease advocacy is rapidly evolving, and nowhere is this more evident than in the Asia-Pacific (APAC) region. While historically less prominent than their Western counterparts, patient advocacy groups (PAGs) in the APAC region have experienced remarkable growth and influence over the past decade. This surge is fuelled by factors such as increased disease awareness, improved access to information, and a growing emphasis on patient-centric healthcare models.

Factors Driving the Growth of Patient Advocacy in APAC

Several key factors have contributed to the burgeoning influence of PAGs in the APAC region:

Rising Disease Awareness:

Increased awareness of rare diseases, facilitated by digital platforms and social media, has empowered patients and families to connect, share experiences, and advocate for their needs.

Improved Access to Information:

The internet has democratized access to information, allowing patients to research their conditions, connect with others facing similar challenges, and stay informed about the latest treatment options.

Shift towards Patient-Centric Care: Healthcare systems across the APAC region are increasingly recognizing the importance of patient perspectives and involvement in decision-making processes.

Government Initiatives: Several APAC governments have introduced policies and initiatives to support rare disease patients and their families, creating a more conducive environment for advocacy efforts.

The Impact of PAG's in the APAC Region

The growing influence of PAGs in the APAC region is evident in their diverse contributions:

Raising Awareness:

PAGs actively educate the public, healthcare providers, and policymakers about rare diseases, their impact on individuals and families, and the need for research, diagnosis, and treatment options.

Advocating for Change:

PAGs are becoming increasingly vocal in their advocacy efforts, lobbying for improved healthcare policies, research funding, and access to affordable treatments. They often work collaboratively with government agencies and other stakeholders to effect change.

Supporting Patients and Families:

PAGs provide crucial support services to patients and their families, including information, emotional support, and resources for navigating the healthcare system.

Empowering Patients:

PAGs empower patients to become active participants in their healthcare journey, advocating for their own needs and shaping the direction of research and development.

Collaborating with Industry:

PAGs are increasingly partnering with pharmaceutical companies to ensure that patient perspectives are integrated into drug development and commercialization strategies. This collaboration can lead to more patient-centric therapies and improved outcomes.

Prominent PAG's in the APAC Region

The APAC region is home to a diverse array of PAGs, each dedicated to supporting specific rare disease communities. Some notable examples include:

The Taiwan Foundation for Rare Disorders (TFRD):

Established in 1999, TFRD is a leading advocacy organization in Taiwan, providing support and resources to rare disease patients and their families.

The Japanese Rare Disease Network (JRDN):

JRDN is a nationwide network of patient organizations and healthcare professionals dedicated to improving the lives of rare disease patients in Japan.

Rare Cancers Australia (RCA):

RCA is a patient-led organization that provides support, information, and advocacy for individuals and families affected by rare cancers in Australia.

The Future of Patient Advocacy in the APAC Region

The future of patient advocacy in the APAC region is bright. As awareness of rare diseases continues to grow, and healthcare systems increasingly embrace patient-centric approaches, PAGs are poised to play an even more significant role in shaping the future of rare disease care.

Partner Rare: Your Strategic Partner in Global Rare Disease Success

At Partner Rare, we recognize the vital role of patient advocacy in achieving success in the complex and evolving landscape of rare disease therapies. We collaborate with PAGs across the globe, fostering meaningful partnerships to ensure that patient voices are heard and your therapy reaches those who need it most.

Whether you are navigating the regulatory pathways in Europe, the US, or the dynamic APAC region, our team of experts has the knowledge and experience to tailor strategies to your specific needs. We understand that each rare disease and its corresponding patient community is unique, and we work tirelessly to ensure your therapy’s impact is maximized across all regions. Contact us today to discover how we can help you achieve success in the global rare disease market.

Disclaimer:

The information provided in this article is for informational purposes only and should not be considered as medical or legal advice. Please consult with qualified healthcare professionals and legal counsel for guidance on specific medical conditions and regulatory requirements.

About the Author

Aaron Blocker MSc.

Aaron Blocker is a Senior Advisor and Consultant specializing in statistics, market access, and healthcare policy. He leverages his master’s in biomedical research and extensive data analytics experience to help pharmaceutical companies and non-profits navigate the complex rare disease landscape. Driven by his personal experience with Hypophosphatasia, Aaron is a passionate patient advocate and sought-after speaker. Combining his academic research and industry expertise, Aaron champions clinical trials, patient recruitment, and scientific progress. He is an active collaborator with global patient advocacy groups, fostering connections that shape product development and market access strategies for rare disease therapies globally.

Meet our experts

Industry’s rare disorders experts creating exceptional outcomes

VIEW TEAM

Taking it forward

Accelerating Your Innovation’s Journey to Market with our bespoke Accelerator Program.